Welcome to our dedicated page for HUTCHMED (China) SEC filings (Ticker: HMDCF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on HUTCHMED (China)'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into HUTCHMED (China)'s regulatory disclosures and financial reporting.
HUTCHMED (China) Ltd director Edith Shih has filed an initial ownership report showing her equity stake in the company. She reports direct holdings of 700,000 ordinary shares and 100,000 American depositary shares. Each American depositary share represents 5 ordinary shares.
HUTCHMED is withdrawing cancer drug TAZVERIK® from Greater China after safety concerns emerged in a major global study. Ipsen, which holds the marketing authorization, is voluntarily withdrawing TAZVERIK in the US following data from the SYMPHONY-1 trial showing secondary blood cancers that may outweigh benefits.
HUTCHMED’s subsidiary has begun market withdrawal and product recalls in the Chinese mainland, Hong Kong and Macau, and has stopped all active tazemetostat clinical trials locally. Healthcare providers and pharmacies have been told to cease prescribing and dispensing the drug, and trial sites must stop using it.
TAZVERIK had conditional approval in China for follicular lymphoma, with ongoing obligations tied to foreign safety signals. HUTCHMED reports that the withdrawal is not expected to affect its overall financial guidance; 2025 TAZVERIK sales were US$2.5 million.
HUTCHMED (China) Limited reports that Independent Non-executive Director Professor Mok Shu Kam, Tony will retire from the Board at the annual general meeting on May 12, 2026 and will not seek re-election. He has served for more than eight years, approaching the nine-year cap on independent director tenure under Hong Kong Listing Rules.
At the conclusion of the meeting, he will cease to be an Independent Non-executive Director and step down from his roles as chairman and member of the Company’s board committees, including the Nomination and Technical Committees. The Board has approved changes to the composition of board committees and the Senior and Lead Independent Non-executive Director role, effective from the end of the meeting, subject to shareholder re-election of the relevant directors. Professor Mok has confirmed he has no disagreement with the Board and that there are no other matters needing shareholder attention regarding his retirement.
HUTCHMED reported 2025 full-year results with revenue of $548.5 million, down 13% from 2024, and net income of $456.9 million, up sharply from $37.7 million. Profit was boosted by a $415.8 million gain on divesting part of SHPL, alongside lower operating expenses.
Oncology/Immunology consolidated revenue fell 21% to $285.5 million, but total in‑market oncology sales grew 5% to $524.7 million, led by 26% FRUZAQLA® growth. Cash, cash equivalents and short-term investments rose to $1.37 billion, and 2026 Oncology/Immunology revenue guidance is $330–$450 million.
HUTCHMED (China) Limited files its annual report detailing 2025 results and key risks around its China-focused oncology business. The company is a Cayman holding structure with operations run mainly through PRC subsidiaries and 872,327,620 ordinary shares outstanding as of December 31, 2025.
The report highlights dependence on three approved oncology drugs and a large pipeline still in development, alongside heavy R&D spending and a 2025 operating cash outflow of $64.7 million after positive operating cash flows in 2023 and 2024. Equity earnings from its Shanghai Hutchison Pharmaceuticals stake fell 51.3% to $22.7 million in 2025 after divesting 45% of that business.
HUTCHMED flags substantial legal and operational risks from PRC oversight, data and cybersecurity rules, the Holding Foreign Companies Accountable Act, and evolving Chinese approval requirements for offshore offerings. It notes FX controls and PRC dividend restrictions, has never paid dividends, and warns it may need substantial additional capital, which could dilute shareholders or add debt.
HUTCHMED has begun a global Phase I/IIa clinical trial of HMPL-A580, its second next-generation Antibody-Targeted Therapy Conjugate (ATTC), in patients with unresectable, advanced or metastatic solid tumors in China and the US. The first patient was dosed on March 4, 2026.
HMPL-A580 links a highly selective PI3K/PIKK small-molecule inhibitor to an anti-EGFR antibody, aiming to exploit synergy between PAM pathway inhibition and EGFR blockade. The study’s dose-escalation phase will determine the recommended dose, followed by expansion cohorts to further assess safety and preliminary anti-tumor activity.
HUTCHMED (China) Limited has scheduled the release of its 2025 final results for March 5, 2026. The announcement will be made at 6:00 am EST, 11:00 am GMT and 7:00 pm HKT, giving investors in major markets simultaneous access.
Management will host two webcast presentations for analysts and investors to review the results and take questions. An English webcast is set for 8:00 am EST on March 5, 2026, and a Putonghua webcast for the Hong Kong and mainland China audience will follow on March 6, 2026. Live and replay access will be available via the company’s website.